IMMUNOTOPE is a clinical stage biotechnology company developing  immunotherapy products for the treatment and prevention of cancer and chronic viral infections.  Our products activate the patient’s own immune system to fight disease and prevent recurrence.  Our comprehensive approach to cancer therapy focuses on the critical, unmet need to diagnose cancer at the very earliest stages and to develop effective treatments that destroy tumors and prevent metastasis. Our product portfolio includes ovarian, breast, prostate, lung, pancreatic and colon cancer and HBV, HCV, HIV, Influenza and Dengue viral vaccines.   

Immunotope's platform provides the ideal combination of technologies for successful immunotherapy.  We are developing products and services that will: 

• Address the need for highly efficacious, curative treatments with minimal toxicity
• Use the exquisite sensitivity and specificity of the immune system for early detection of cancer
• Provide innovative tools and services for collaborative development of novel drug and diagnostic products
• Provide our shareholders with exceptional returns on their investment

We use proprietary immunoproteomics technologies to identify naturally processed and presented antigens associated with Major Histocompatibility Complex Class I and Class II molecules that are present only on diseased cells. Immunotope’s lead product is the IMT-1012 Immunotherapeutic Vaccine, a multivalent cancer therapeutic mixture of twelve different novel antigens, each of which targets a separate, critical pathway known to be present in highly aggressive tumors. After successfully completing a Phase I clinical trial in ovarian and breast cancer patients, Immunotope has licensed 7 antigens from IMT-1012 to Immunovaccine Inc., Halifax, Canada, a vaccine company with DepoVax delivery system.  Immunovaccine is conducting a phase I clinical study of DPX-0907 in ovarian, breast and prostate cancer patients.

Immunotope has completed pre clinical characterization studies and preparing for phase I clinical study in lung and pancreatic cancer.  Immunotope is at the pre clinical stage with therapeutic vaccine development in HCV and HIV and indications and universal prophylactic vaccine development for influenza and dengue virus infections.

Immunotope has partnered with Midatech Ltd, UK, a company with gold nanoparticle delivery system and initiated SynTara LLC, a joint venture entity for efficient and complete therapeutic vaccine products commercialization. 

Immunotope is also applying its platform technology to develop novel autoantibody-based biomarkers for early-stage detection of cancer. Performed as a simple blood test, our products will be rapid, non-invasive and indication-specific early-stage cancer diagnostics.